10-Q: Forte Biosciences Reports Q1 2024 Results, Progresses FB102 Clinical Trial

Forte Biosciences reported a net loss of $7.4 million for the first quarter of 2024, while advancing its FB102 clinical trial.

Summary

• Forte Biosciences, a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2024, reporting a net loss of $7.4 million.
• The company's research and development expenses were $4.4 million, a decrease from $4.8 million in the same period last year, primarily due to lower manufacturing costs offset by increased clinical trial expenses.
• General and administrative expenses increased to $3.5 million from $2.1 million, mainly due to higher legal and professional fees, including litigation expenses.
• Forte's cash and cash equivalents stood at $30.4 million as of March 31, 2024, which the company believes will be sufficient to fund operations for at least 12 months.
• The company is focused on developing its FB102 program, which is currently in a Phase 1 clinical trial, with plans to initiate patient-based studies in 2024.
• Forte anticipates continued operating losses as it advances FB102 through clinical trials and will need to raise additional capital in the future.
• The company has ongoing legal proceedings, including a books and records action and a class action lawsuit, which are being vigorously defended.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is making progress with its clinical trial, the financial results are weak, and there are significant risks and uncertainties. The ongoing legal issues and the need for additional capital are also concerning.

Positives

• Forte Biosciences has sufficient cash to fund operations for at least 12 months.
• The company has successfully completed three cohorts of single ascending doses in its Phase 1 clinical trial for FB102.
• The company has commenced cohorts of multiple ascending doses of FB102.
• Forte plans to initiate patient-based studies in 2024.

Negatives

• Forte Biosciences reported a net loss of $7.4 million for the first quarter of 2024.
• The company's accumulated deficit is $125.9 million.
• General and administrative expenses increased significantly due to litigation expenses.
• The company is involved in ongoing legal proceedings.
• Forte is restricted in its ability to access additional funding from the sale of securities under Form S-3.

Risks

• Forte's business is heavily dependent on the success of FB102, which is still in early clinical development.
• The company has a history of net losses and expects to incur further losses in the future.
• Forte will require additional capital to fund its operations and there is no guarantee that additional funding will be available.
• Clinical development is a lengthy and expensive process with an uncertain outcome.
• The company faces significant competition from other healthcare companies.
• The market price of Forte's common stock is expected to be volatile.
• The company is currently non-compliant with Nasdaq's minimum bid price requirement, which could result in delisting.
• The company is involved in ongoing legal proceedings which could be costly and divert management's attention.
• The company may experience material weaknesses in its internal control over financial reporting.

Future Outlook

The company expects to continue to incur operating losses as it advances FB102 through clinical trials and will need to raise additional capital in the future. They anticipate initiating patient-based studies in 2024.

Management Comments

• Management expects to continue to incur additional losses in the foreseeable future as the Company focuses its development efforts on advancing FB102 through clinical trials.
• The Company believes that its existing cash and cash equivalents will be sufficient to allow the Company to fund its operations for at least 12 months from the filing date of this Form 10-Q.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on autoimmune and autoimmune-related diseases, which is a growing market with significant unmet needs. The company's FB102 program targets key pathways implicated in these indications, which aligns with current industry trends in developing targeted therapies.

Comparison to Industry Standards

• Forte's cash burn of $6.7 million in operating activities for the quarter is typical for a clinical-stage biotech company, but it is important to compare this to peers with similar pipelines and development stages.
• Companies like Xencor (XNCR) and Arcus Biosciences (RCUS), which are also developing immunotherapies, have similar cash burn rates, but they also have multiple programs in development, which may justify higher spending.
• Forte's R&D expenses of $4.4 million are lower than some of its peers, which may indicate a more focused approach or a slower pace of development.
• The increase in G&A expenses to $3.5 million, driven by litigation costs, is a concern and should be monitored closely, as it could impact the company's ability to fund its R&D programs.
• The company's cash position of $30.4 million is relatively low compared to some of its peers, which may require them to raise additional capital sooner than expected.

Management Changes

Legal Proceedings

• Camac Fund L.P. v. Forte Biosciences Inc., a books and records action, remains pending.
• Camac Fund, LP v. Paul A. Wagner, et al., a class action and derivative complaint, is ongoing with a trial scheduled for July 29-31, 2024.
• Forte Biosciences, Inc. v. Camac Fund, LP, et al., a complaint alleging deceit and misinformation, is ongoing with a motion to dismiss awaiting a ruling from the Court.

Related Party Transactions

• One member of the Company's board of directors received cash payments of $29,000 for scientific consulting services during the three months ended March 31, 2024.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential cost-cutting measures if the company faces financial difficulties.
• Customers (potential patients) may benefit from the development of FB102 if it proves to be effective.
• Suppliers and creditors may be impacted by the company's financial performance and ability to pay its obligations.

Next Steps

• The company plans to continue advancing its FB102 program through clinical trials.
• The company anticipates initiating patient-based studies in 2024.
• The company will continue to monitor the potential impacts of global events on its business.
• The company will continue to pursue its legal claims and defend against claims made against it.

Key Dates

Keywords

FB102, clinical trial, biopharmaceutical, autoimmune diseases, graft-versus-host disease, vitiligo, alopecia areata, research and development, financial results, net loss, cash equivalents, Nasdaq, legal proceedings